Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating and $23.00 price target

Analyst Ratings For Aquestive Therapeutics Inc (NASDAQ:AQST)

Today, Royal Bank of Canada initiated coverage on Aquestive Therapeutics Inc (NASDAQ:AQST) with a Outperform with a price target of $23.00.

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aquestive Therapeutics Inc (NASDAQ:AQST) is Buy with a consensus target price of $26.00 per share, a potential 62.20% upside.

Some recent analyst ratings include

  • 8/20/2018-Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating and $23.00 price target
  • 8/20/2018-Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating and $29.00 price target
  • 8/20/2018-Aquestive Therapeutics Inc (NASDAQ:AQST) has coverage initiated with a Outperform rating


    Recent Trading Activity for Aquestive Therapeutics Inc (NASDAQ:AQST)
    Shares of Aquestive Therapeutics Inc closed the previous trading session at 16,02 +0,020 0,13 % with 101453 shares trading hands.

    An ad to help with our costs